A combination of two tissue repair peptides. BPC-157 contributes localised healing and angiogenesis while TB-500 contributes systemic anti-inflammatory action and tissue remodelling. No published clinical study has tested the pairing itself in people, and the one preclinical study that did test the combination found no added benefit over either peptide alone.
A combination of two tissue repair peptides. BPC-157 contributes localised healing and angiogenesis while TB-500 contributes systemic anti-inflammatory action and tissue remodelling. No published clinical study has tested the pairing itself in people, and the one preclinical study that did test the combination found no added benefit over either peptide alone.
Tissue Repair
Recovery Support
Injury Research
What the research reports
Benefits of BPC-157 + TB-500
Outcomes described across the published BPC-157 + TB-500 literature and ongoing study. Read each as research context, not a promised result.
01
Combined repair mechanisms
Pairs localised angiogenic action with systemic actin regulation, the stated rationale for stacking the two peptides though the one direct preclinical test of the combination found no added benefit over either peptide alone. Reported in research settings.
02
Recovery support research
Popular in athletic recovery contexts for tendon, muscle and joint work, though the combination itself has no published clinical trial. Reported in research settings.
03
Localised and systemic reach
BPC-157 is often injected near the injury while TB-500 is dosed systemically, giving the blend two different routes of action. Reported in research settings.
04
Convenience of one protocol
Combining both into a single weekly schedule reduces the number of separate protocols to track during a research period. Reported in research settings.
05
Component level study evidence
Each peptide has its own preclinical record, and the one study testing the combination directly found no added effect from combining them versus either peptide alone. Reported in research settings.
Clinical evidence
Clinical evidence and study base
The published record, labeled by strength so you can see what is settled and what is still emerging.
No combination trials found
No published clinical study of the BPC-157 and TB-500 combination has been identified in humans. The nearest direct evidence is a 2026 rat study that found combining the two peptides produced no additional benefit over either one alone, with the authors attributing this to both peptides converging on the same repair pathway. Reported in the cited paper.
The nearest human data is a 2021 case series where 87.5 percent of knee pain patients improved on BPC 157 given alone or together with thymosin beta-4. Reported in the cited paper.
A 2016 review of thymosin beta-4 reported faster dermal repair in chronic wounds, which is the component evidence behind the TB-500 half of this blend. Reported in the cited paper.
Added in GLOW style blends for collagen and elastin signalling alongside the two repair peptides.
KPV peptide
Added in KLOW style blends to target inflammatory signalling through the melanocortin derived pathway.
Ipamorelin
No known negative interaction. The growth hormone axis is separate from both repair mechanisms here.
Semaglutide
No known negative interaction. Metabolic and tissue repair pathways do not overlap meaningfully.
Questions
Frequently asked questions.
What is BPC-157 + TB-500?
BPC-157 + TB-500 is a combination of two tissue-repair peptides sold together as a single research blend. BPC-157 is studied for localised healing and angiogenesis, while TB-500 (thymosin beta-4) is studied for systemic actin regulation and tissue remodelling, many researchers compare supplier quality, purity, and testing data before purchasing either peptide alone or as this blend.
What are the research benefits of BPC-157 + TB-500?
Each peptide has its own preclinical and limited human evidence individually, but the one study that directly tested the combination, a 2026 rat study found no additional benefit from combining them over either peptide alone, likely because both act on overlapping repair pathways. Research interest in the blend is largely about convenience of a single protocol, not demonstrated synergy, so buyers should weigh that against purity, dose, and independent lab verification before choosing a source.
How does BPC-157 + TB-500 work?
BPC-157 is studied for localised, injury-site action including angiogenesis, while TB-500 is studied for systemic effects through actin regulation. As with any research peptide blend, how it's formulated, dosed, and tested matters as much as the compounds themselves, which is why verified suppliers and transparent COAs are important, especially since this specific pairing hasn't been clinically tested together in people.
Is BPC-157 + TB-500 for research use only?
Yes. Products like this blend are intended for research, laboratory, or educational use and are not marketed as approved human therapeutics. No published clinical study has tested the BPC-157 and TB-500 combination in people. Always follow local laws, lab safety practices, and institutional requirements before handling or studying any peptide.
What should I look for before buying BPC-157 + TB-500?
Key checks include verified COA data, peptide form and concentration, supplier reputation, stock status, and cost per mg. Since the combination itself lacks dedicated clinical evidence, it's also worth confirming the blend's actual ratio of BPC-157 to TB-500 before comparing pricing across suppliers, rather than assuming all "blend" listings are equivalent.